EGFR and lung carcinoma: MMAE-conjugated VBC101-F11 displayed superior TGI over ABBV-399 in lung cancer cell line xenografts (3 mg/kg), and conjugation to a novel, undisclosed DNA replication inhibitor resulted in similar efficacy to AZD9592 in EGFR-low/c-MET-high and EGFR-/c-MET-moderate models [148].